Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 5/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.67 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | IL18 | Q14116 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11054945 | 0.90 | MAPT (0.81) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL4665207 | 0.86 | MAPT (0.74) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL20941635 | 0.86 | MAPT (0.75) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL4741253 | 0.84 | MEN1 (0.76) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL11048619 | 0.84 | MEN1 (0.76) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL16782007 | 0.84 | MEN1 (0.75) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL4349313 | 0.83 | MAPT (0.70) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL11056656 | 0.83 | MAPT (0.75) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL22834250 | 0.82 | CNR1 (1.00) | MAPTLMNAHTTNLRP3TSHR | |
| SCHEMBL4358449 | 0.82 | MAPT (0.69) | MAPTLMNAHTTNLRP3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150878-A1 | Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-06-04 | — | — | US | claimed |
| WO-2013152223-A2 | METHODS FOR INHIBITING VIRUSES BY TARGETING CATHEPSIN-L CLEAVAGE SITES IN THE VIRUSES' GLYCOPROTEINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-10-10 | — | — | WO | claimed |
| US-20150150878-A1 | Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-06-04 | — | — | US | disclosed |
| US-20150150878-A1 | Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-06-04 | — | — | US | disclosed |
| US-20150150878-A1 | Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2015-06-04 | — | — | US | disclosed |
| WO-2013152223-A2 | METHODS FOR INHIBITING VIRUSES BY TARGETING CATHEPSIN-L CLEAVAGE SITES IN THE VIRUSES' GLYCOPROTEINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013152223-A2 | METHODS FOR INHIBITING VIRUSES BY TARGETING CATHEPSIN-L CLEAVAGE SITES IN THE VIRUSES' GLYCOPROTEINS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LIMITED (GB) | 2012-08-23 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | PROSIDION LTD. (GB) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150878-A1 | Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins | CTSL, CTSH, CTSV | MAPT 3447/4885LMNA 886/4885HTT 1874/4885 |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | MAPT 1654/4885LMNA 4283/4885HTT 1736/4885 |
| US-20080261952-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885LMNA 4374/4885HTT 1967/4885 |
| US-20120214808-A1 | Aryl Urea Derivatives for Treating Obesity | CNR1, GPR119, UTS2R | MAPT 4151/4885LMNA 4374/4885HTT 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.